Key Highlights from the EMA’s 2023 Annual Report: Advancing Medicines and Health

The European Medicines Agency’s 2023 annual report highlights its efforts to protect public and animal health in the EU. The report covers key achievements in cancer medicines, data-driven medicine regulation, and transparency. EMA recommended 77 medicines for human use, including 39 with new active substances, and 14 veterinary medicines, nine of which had new active substances. Notably, two RSV vaccines and the first CRISPR/Cas9 gene-editing therapy were approved. EMA also launched the “Cancer Medicines Pathfinder” initiative to enhance cancer drug development and approval. The report emphasizes the importance of data in regulating medicines and improving transparency through effective communication with the public. The digital report version offers interactive features, while a print-ready PDF is also available.¹

Continue reading here.

References

1. European Medicines Agency. (2024). The European Medicines Agency’s contribution to science, medicines and health in 2023. Publications Office of the European Union. https://www.ema.europa.eu/en/documents/annual-report/2023-annual-report-european-medicines-agency_en.pdf

Disclaimers

• The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
• Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
• No official support by any organization(s) has been provided or should be inferred

Recommended Reads

• EMA news: Establishing efficacy based on single-arm trials in marketing authorisations
• India’s ascendancy in 2023
• EMA recommends first vaccine to protect older adults from RSV
• Is There a Benefit to the Covid-19 Pandemic?
• COVID-19 Vaccine Development and Testing at a Record-Setting Rate